Tope Adeyomola
Psychiatric/Mental Health · Fort Worth, TXNPI 1285186965
Payments from drug & device makers
Across 468 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$889
- Alkermes, Inc.$873
- Teva Pharmaceuticals USA, Inc.$853
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$799
- Neurocrine Biosciences, Inc.$740
- Johnson & Johnson$706
- plus $2K from 10 others
What the payments were for
- Food & beverage$7,17898%
- Education$1582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $889 |
| Alkermes, Inc. | 46 | $873 |
| Teva Pharmaceuticals USA, Inc. | 54 | $853 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $799 |
| Neurocrine Biosciences, Inc. | 28 | $740 |
| Johnson & Johnson | 40 | $706 |
| Otsuka America Pharmaceutical, Inc. | 33 | $493 |
| E.r. Squibb & Sons, L.L.C. | 38 | $436 |
| Sunovion Pharmaceuticals Inc. | 46 | $398 |
| Vanda Pharmaceuticals Inc. | 19 | $362 |
| Indivior Inc. | 23 | $341 |
| Lundbeck LLC | 14 | $278 |
| Axsome Therapeutics, Inc. | 4 | $71 |
| Luye Pharma (USA) Ltd. | 2 | $43 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
How this compares
$7,336 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 39 | $328,331 |
| Invega SustennaPaliperidone Palmitate | 79 | $266,594 |
| AustedoDeutetrabenazine | 34 | $241,758 |
| CaplytaLumateperone Tosylate | 27 | $44,008 |
| AristadaAripiprazole Lauroxil | 12 | $42,393 |
| Lurasidone Hcl | 130 | $23,207 |
| RexultiBrexpiprazole | 15 | $22,536 |
| VraylarCariprazine Hcl | 15 | $21,360 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,153 |
| Quetiapine Fumarate | 362 | $6,275 |
| Divalproex Sodium ErDivalproex Sodium | 116 | $4,699 |
| Olanzapine | 224 | $4,084 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 18 | $3,769 |
| Clozapine | 17 | $3,762 |
| Trazodone Hcl | 569 | $3,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $740 | $328,33139 claims |
| Johnson & JohnsonInvega Sustenna | $706 | $266,59479 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $853 | $241,75834 claims |
| Alkermes, Inc.Aristada, Lybalvi | $873 | $59,54623 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $799 | $44,00827 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $493 | $22,53615 claims |
| AbbVieVraylar | $889 | $21,36015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Fort Worth
- Tamekia ScaggsFort Worth$80K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.